GlassScriptPhysician profile
Sirajuddin Ismail
NPI 1902822901
$2,843.30
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $173 · 2021: $241 · 2022: $433 · 2023: $684 · 2024: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,418.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $779.11 | 2019-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $404.15 | 2019-2023 | Uzedy, Austedo Xr |
| Axsome Therapeutics, INC. | $304.52 | 2023-2024 | Auvelity, Sunosi |
| Abbvie INC. | $267.01 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $173.79 | 2022-2023 | |
| Acadia Pharmaceuticals INC | $162.41 | 2019-2024 | Nuplazid |
| Vanda Pharmaceuticals INC. | $126.50 | 2024 | Fanapt |
| Mdd US Operations, LLC | $125.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $119.99 | 2020 | |
| Biogen, INC. | $100.00 | 2024 | Zurzuvae |
| Alkermes, INC. | $88.27 | 2022 | |
| Sunovion Pharmaceuticals INC. | $88.03 | 2019 | |
| Allergan, INC. | $86.95 | 2019 | |
| Supernus Pharmaceuticals, INC. | $17.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sirajuddin Ismail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.